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Available online 19 April 2016Background: We report a ﬁrst-in-human trial evaluating safety and immunogenicity of a recombinant BCG,
AERAS-422, over-expressing TB antigens Ag85A, Ag85B, and Rv3407 and expressing mutant perfringolysin.
Methods: This was a randomized, double-blind, dose-escalation trial in HIV-negative, healthy adult, BCG-naïve
volunteers, negative for prior exposure toMtb, at one US clinical site. Volunteers were randomized 2:1 at each
dose level to receive a single intradermal dose of AERAS-422 (N105–b 106 CFU = low dose,
≥106– b 107 CFU= high dose) or non-recombinant Tice BCG (1–8 × 105 CFU). Randomization used an indepen-
dently prepared randomly generated sequence of treatment assignments. The primary and secondary outcomes
were safety and immunogenicity, respectively, assessed in all participants through 182 days post-vaccination.
ClinicalTrials.gov registration number: NCT01340820.
Findings: Between Nov 2010 and Aug 2011, 24 volunteers were enrolled (AERAS-422 high dose, n=8; AERAS-422
low dose, n=8; Tice BCG, n=8); all were included in the safety and immunogenicity analyses. All 24 subjects had
at least one adverse event, primarily expected local reactions. High dose AERAS-422 vaccination induced Ag85A-
and Ag85B-speciﬁc lymphoproliferative responses and marked anti-mycobacterial activity in a whole blood bacte-
ricidal activity culture assay (WBA), but was associated with varicella zoster virus (VZV) reactivation in two vacci-
nees. These volunteers displayed high BCG-speciﬁc IFN-γ responses pre- and post-vaccination possibly
predisposing them to autocrine/paracrine negative regulation of immune control of latent VZV. A systems biology
transcriptomal approach identiﬁed positive correlations between post-vaccination T cell expression modules and
WBA, and negative correlations between post-vaccinationmonocyte expressionmodules andWBA. The expression
of one key macrophage marker (F4/80) was constitutively elevated in the two volunteers with zoster.
Interpretation: The unexpected development of VZV in two of eight healthy adult vaccine recipients resulted in dis-
continuation of AERAS-422 vaccine development. Immunological and transcriptomal data identiﬁed correlations
with the development of TB immunity and VZV that require further investigation.
Funding: Aeras, FDA, Bill and Melinda Gates Foundation.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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. This is an open access article under1. Introduction
The World Health Organization (WHO) has declared tuberculosis
(TB) a global health emergency and a new vaccine is desperately need-
ed. The development of recombinant bacillus Calmette-Guerin (BCG),
which improves upon the wild type attenuated Mycobacterium bovisthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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posed approach (Horwitz et al., 2000; Velmurugan et al., 2013).
AERAS-422 is a recombinant BCG (rBCG) derived from the Danish
1331 strain of BCG (Sun et al., 2009). AERAS-422 includes a chromo-
somal gene coding for a mutant perfringolysin (PFOG137Q) derived
from Clostridium perfringens. Phagocytosis of AERAS-422 by human
macrophages does not result in cell lysis. PFOG137Q retains the ability
to perforate endosomal membranes, allowing antigens to enter the cy-
tosol and thus stimulate an MHC Class I-restricted immune response.
AERAS-422 contains a plasmid encoding selected immunodominant an-
tigens expressed by Mtb during both active infection (Rv3804c and
Rv1886c, aka Ag85A and Ag85B, respectively), and reactivation of latent
infection (Rv3407).
AERAS-422 is a genetically stable rBCG capable of priming strong
and more persistent CD8+ T cell responses in mice than nonrecombi-
nant BCG or other rBCGs (Sun et al., 2009). Preliminary data from im-
munodeﬁcient (SCID) mice indicate that AERAS-422 is signiﬁcantly
more attenuated than nonrecombinant BCG (Sun et al., 2009). We re-
port the ﬁrst administration of AERAS-422 in humans to evaluate safety
and immunogenicity.
2. Methods
2.1. Study Design
A Phase I, randomized, double-blind, dose-escalation studywas con-
ducted at Saint Louis University (SLU), following Declaration of Helsinki
principles and approved by SLU and Aeras Institutional Review Boards.
2.2. Participants
After giving written informed consent, 24 HIV-negative, BCG-naïve,
mycobacteria-naïve, 18–40 year old healthy subjects were sequentially
assigned to study groups.
2.3. Randomization and Masking
The ﬁrst 12 subjects were randomized 2:1 to receive either AERAS-
422 low-dose (≥105 to b106 CFU) or Tice® BCG. After review of day
28 blinded safety data by the principal investigator and local medical
monitor, 12 more subjects were randomized to receive either AERAS-
422 high-dose (≥106 to b107 CFU) or Tice BCG. All vaccinations were
given intradermally. Randomization was according to a randomly gen-
erated sequence of treatment assignments, prepared by an independent
statistician and provided in a sealed envelope. Doses of vaccine were
prepared in identical syringes by the study vaccine manager at the
site, who was unmasked to treatment allocation. The volunteers, study
staff administering vaccinations or undertaking follow-up clinical as-
sessments, and laboratory staff weremasked to treatment assignments.
2.4. Procedures
Subjects were followed at 3, 7, 14, 28, 56, 84, 112, 140, and 182 days
post-vaccination.
2.5. Intracellular Cytokine Staining Assay (ICS) (7-color)
Refer to the Supplementary materials for details.
2.6. Whole Blood Lymphoproliferative Assay
Whole blood sampleswere diluted ten foldwithRPMI and expanded
with optimal doses of Ag85B peptide pool (15-mers overlapping by 11
amino acids covering the entire protein sequence), rAg85b protein,
live BCG, or rested in medium for 7 days at 37 °C in 5% CO2. During
the last 10–14 h, cultures were pulsed with tritiated thymidine andcell-incorporated radioactivity measured (results are presented as
dpm).2.7. Whole Blood Bactericidal Activity (WBA) Against Tice BCG
Mycobactericidal activity was studied in whole blood cultures as
previously described (Hoft et al., 2002; Worku & Hoft, 2003; Cheon
et al., 2002; Fletcher et al., 2013). Changes in the log10 viable bacilli
from days 0 to 4were calculated as: log10 (ﬁnal/initial). Results were re-
ported as log change per day of whole blood culture. Datamanagement,
standard curves, interpolation, and calculation of log10 CFU were per-
formed using customized computer software from author RSW (full
protocol and software available on request).2.8. RNA Collection, Processing, Sequencing, and Statistical Analyses
Refer to the Supplementary materials for details.2.9. Transcription Module Over-representation Analyses
Blood transcriptome module over-representation analyses were
performed using module annotations previously provided (Obermoser
et al., 2013; Li et al., 2014). Statistical signiﬁcance of module over-
representationwas assessed by Fisher's Exact Test,withmultiple testing
adjustment performed using the Benjamini-Hochberg algorithm.
Module-level expression values were computed by averaging over the
log2 expression levels of all genes comprising a given module.2.10. Outcomes
The primary and secondary outcomes were safety and immunoge-
nicity, respectively, assessed in all participants through 182 days post-
vaccination. The safety proﬁle was assessed by evaluation of solicited
and unsolicited AEs through day 56, and serious AEs through day 182.
Injection site reactions, axillary tenderness, headache, myalgia, arthral-
gia, fatigue and temperature were recorded by the subject on diary
cards for 7 days after vaccination. Additional safety evaluations are de-
scribed in the Supplementary materials.2.11. Statistical Analysis
The sample size was selected as adequate for initial review of the
safety proﬁle of AERAS-422; the studywas not powered to detect differ-
ences in AEs between dose groups. All volunteers were included in the
safety and efﬁcacy analyses. Friedman repeated-measures analysis of
variance (ANOVA)was used to study overall increases after vaccination,
the Wilcoxon matched-pairs test was used to identify signiﬁcantly in-
creased post-vaccination compared with matched pre-vaccination re-
sponses, and the Mann-Whitney U test was used to compare
responses between groups. McNemar's test and Fisher's exact test
were used to compare paired and unpaired categorical data, respective-
ly. Analyses were completed with Statistica (Statsoft).
The trial is registered with ClinicalTrials.gov (number:
NCT01340820).2.12. Role of the Funding Source
Aeraswas the trial sponsor and contributed to study design and data
analysis. The other funders had no role in study design, data collection,
data analysis, data interpretation, or writing of the report. The corre-
sponding author had full access to all the data in the study and had
ﬁnal responsibility for the decision to submit for publication.
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3.1. Study Subjects and Safety Evaluation
Between Dec 06, 2010 and Aug 05, 2010, 24 volunteers were en-
rolled (AERAS-422 high dose, n= 8; AERAS-422 low dose, n= 8; Tice
BCG, n= 8); all were included in the safety and immunogenicity anal-
yses. All 24 randomized subjectswere vaccinated on day 0 and complet-
ed the 182-day trial (Consort Diagram, Fig. 1). There were no major
differences in demography between the groups (Supplemental
Table 1). All subjects had at least one adverse event (AE; Supplemental
Table 2). Adverse events primarily involved the expected local reactions
known to occur with intradermal BCG vaccination. There were no clin-
ically signiﬁcant differences in these AEs between the groups (see Sup-
plementary materials for further details).3.2. Unexpected Safety Signal
Unexpectedly, VZV reactivation (zoster) occurred in two of eight
volunteers in the AERAS-422 high dose group. One volunteer, a previ-
ously healthy 38 year old Caucasian male, reported to the study clinic
64 days after vaccinationwith a painful rash over his left scalp and fore-
head, sinus congestion, and diffuse headache (Fig. 2). A second volun-
teer (a 21 year old Caucasian male) presented to an urgent care center
86 days post-vaccination with a mild to moderate painful vesicular
rash over the posterior left shoulder (data not shown). These volunteers
were treated with acyclovir or famciclovir, steroids (ﬁrst volunteer
only), and pain medication. All signs and symptoms resolved over
2 months without residual pain or other sequela for the ﬁrst volunteer
andwithin 22days for the second volunteer (except for hypopigmented
spots over the VZV-presenting area). A clinical diagnosis of zoster was
made for both volunteers, and conﬁrmed by signiﬁcant increases in
VZV-speciﬁc antibody titers (1:16 pre-vaccination to 1:2048 post-
zoster for the ﬁrst volunteer; 1:2 pre-vaccination to 1:256 post-zoster
for the second volunteer; determined by Quest Diagnostics). The diag-
nosis for the ﬁrst volunteer was conﬁrmed by PCR of punch biopsyFig. 1. Consortmaterial. PCR of punch biopsy tissue from the second volunteer, done
N1 week after symptom resolution, was negative for VZV.
When itwas determined that the two volunteers with zoster had re-
ceived AERAS-422, after unblinding was requested by the study Data
Safety Monitoring Board, clinical development of AERAS-422 was
discontinued. All 24 volunteers had serial VZV serology completed by
a highly sensitive and speciﬁc indirect immunoﬂuorescence assay
(FAMA) to conﬁrm the clinical diagnoses and rule out subclinical reacti-
vation in any additional volunteers (Williams et al., 1974). No other sub-
jects had increased VZV titers post-vaccination.
The remainder of this report focuses on investigations designed to
explore themechanism for zoster reactivation, as well as the expression
of immune and gene patterns induced by the different vaccinations.3.3. Antigen-speciﬁc T Cell Responses
Whole blood lymphoproliferation responses stimulated by overex-
pression of AERAS-422 recombinant antigens were studied in real-
time during the trial. High dose AERAS-422 induced signiﬁcant in-
creases in both Ag85A and Ag85B responses 84 days post-vaccination
(p b 0.05 compared with day 0 byWilcoxon matched pairs testing); in-
creases in Ag85A or Ag85B responses were not observed after Tice BCG
or low dose AERAS-422 (Fig. 3A). No vaccinations were associated with
induction of post-vaccination Rv3407-speciﬁc responses. Despite nega-
tiveQuantiFERONTBGold tests andnohistory of either knownTB expo-
sure or previous BCG vaccination, BCG in vitro stimulation induced
substantial IFN-γ responses compared with medium and recombinant
antigen stimulations in all groups, even prior to Tice or AERAS-422 vac-
cination. After in vitro restimulation with live wild type Tice BCG
(Fig. 3B), all three vaccination groups developed similar increases in
BCG-induced responses.
Whole blood IFN-γ secretion levels weremeasured as an estimate of
overall vaccine-induced type 1 (CD4+Th1 and CD8+Tc1) immune re-
sponses aftermedium rest, recombinant antigen stimulation at two sep-
arate antigen concentrations, and BCG at three different MOIs
stimulation (Fig. 3C). Signiﬁcantly increased IFN-γ responses post-Diagram.
Fig. 2. Subject with VZV reactivation 2 months after AERAS-422 vaccination. Shown are
pictures of the 38 yo male who presented with a rash located on the left scalp and
forehead, bilateral sinus congestion, sinus pain on the left, and diffuse headache
described as aching and pressure 64 days after receiving AERAS-422. Examination of the
skin lesion on the face (left side of the scalp to forehead) revealed a vesicular rash with
pustules and scabs on an erythematous base in the CN5 V1 dermatome (A). There was
also erythema of the left cornea, per examination by an ophthalmologist, as well as an
erythematous and edematous left eyelid (data not shown). After zoster diagnosis and
treatment, the subject was seen on day 84, when the condition had noticeably improved
(B). The subject completed the study through the day 182 evaluation, at which time the
herpes zoster reactivation was resolved with no sequelae (C).
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overexpressed recombinant antigens or BCG in any vaccine group.
However, three volunteers, (one in the high dose AERAS-422 group,
two in the Tice group), produced N10.000 pg/ml of IFN-γ even in the
rested condition (data not shown).
When these three volunteers were excluded from the analysis, none
of the vaccines induced detectable increases in IFN-γ following stimula-
tionwith the three recombinant antigens (Fig. 3D). In contrast, all three
vaccine groups demonstrated similar post-vaccination increases in IFN-
γ in response to restimulation with BCG, some of which were signiﬁ-
cantly increased compared with pre-vaccination (Wilcoxon matched
pairs testing, p b 0.05). The highest post-vaccination BCG-speciﬁc re-
sponses were observed in the high dose AERAS-422 group, however,
the overall responses for this group were not signiﬁcantly higher than
in the other two groups.
The two volunteers who suffered zoster post-vaccination displayed
ﬁve-ten fold higher responses pre-vaccination after in vitro restimula-
tion with BCG (Fig. 4B) compared with the other volunteers (excluding
the high spontaneous IFN-γ producer) in the high dose AERAS-422
group (Fig. 4A), responses that were further augmented by AERAS-
422 vaccination.
Intracellular cytokine responses (ICS) in frozen PBMC were also
studied (Supplemental Fig. 1). No statistically signiﬁcant increases incytokine response were seen post-vaccination after restimulation with
Rv3407, Ag85A, or Ag85B in any of the three treatment groups (see Sup-
plementary materials for further details).3.4. Inﬂammatory Responses in Human Monocytes
To address whether AERAS-422 induces a more robust innate im-
mune cell inﬂammatory cytokine response than wild type BCG strains,
human monocytes were infected with one of two strains of wild type
BCG (Tice and Danish) or AERAS-422 and the production of secreted
IL-1β and TNF-αmeasured. AERAS-422 did not induce exaggerated in-
ﬂammatory cytokine responses, even after 72 h of infectionwith a wide
range of MOI up to amaximumof 30 CFU/monocyte for each BCG strain
(Fig. 5A).3.5. Potential Involvement of IFN-γ-speciﬁc Autoimmunity in VZV
Reactivation
To explore a genetic basis for predisposition to AERAS-422-induced
zoster, HLA typing was completed for all subjects (data not shown).
One of the volunteers who developed zoster was determined to express
DRB1 16:01, very similar to the DRB1 16:02 allele previously associated
with an autoimmune response targeting IFN-γ with neutralizing auto-
antibodies (Kampitak et al., 2011; Browne et al., 2012; Chi et al.,
2013). The other zoster-positive volunteer exhibited DQB1 05:01 allele
expression, closely related to the DQB1 05:02 allele, also associatedwith
IFN-γ autoimmunity.
To test whether the exaggerated IFN-γ responses observed in both
individuals with zoster were related to an autoimmune response lead-
ing to enhanced neutralization of IFN-γ biologic activity, plasma from
all volunteers in the high dose AERAS-422 group was tested for the
presence of IFN-γ neutralizing activity. Plasma harvested on day 56
(Fig. 5B), pre-vaccination and on day 84 (data not shown) did not dis-
play IFN-γ neutralization activity. Two volunteers in the high dose
AERAS-422 group with no VZV reactivation also were determined to
possess the DQB1 05:01 allele.3.6. Whole Blood Bactericidal Activity Against Mycobacteria
Pre-vaccination, whole blood from subjects in both the Tice and
AERAS-422 arms allowed 0.5 log BCG growth over 4 days (0.13 log/
day). No statistically signiﬁcant changes inWBA from baseline emerged
in the Tice BCG group (Fig. 6), or the low dose AERAS-422 group (data
not shown). In the high dose AERAS-422 group, statistically signiﬁcant
inhibition of growth compared to baseline was apparent by day 84,
and signiﬁcant bactericidal activity persisted on day 182 (Fig. 6). Any
positive delta log/d result indicates net growth of BCG during the
whole blood/BCG co-culture period. The mean delta log/day value of
−0.035 for the high dose AERAS-422 group on day 182 means the im-
mune responses in whole blood could kill mycobacteria. This has
never been seen before in previous TB vaccine trials. The two volunteers
who developed zoster did not exhibit distinctly high or low WBA re-
sponses compared to other volunteers receiving high dose AERAS-422.3.7. Myeloid Inﬂammatory Immune Responses
RNA sequencing of whole PBMC harvested pre- and post-
vaccination was performed (Supplemental Fig. 2). In contrast to our
previous work analyzing vaccine-induced innate immune responses
that revealed differential expression of over 1000 genes (Zak et al.,
2012), onlyweak responses were observed after BCG and rBCG vaccina-
tion (see Supplementary materials for further details).
Fig. 3. Vaccine-induced lymphoproliferative and IFN-γ responses induced by wild type, low dose AERAS-422 and high dose AERAS-422 BCG. Whole blood was collected pre- and post-
vaccination and stimulated in vitro with different antigens (the recombinant proteins overexpressed by AERAS-422 and live Tice BCG). Antigen-speciﬁc lymphoproliferative responses
were studied at days 0 (pre-vaccination), 84 (3 months post-vaccination) and 182 (6 months post-vaccination) (A and B). Antigen-speciﬁc IFN-γ responses stimulated in vitro with
the recombinant proteins and different MOIs of Tice BCG at days 0, 28, 56, 84, and 182 are shown for all volunteers (C) and excluding the three volunteers with high spontaneous
baseline responses (D). Mean and standard error responses are presented. *p b 0.05 by Wilcoxon matched pairs test.
Fig. 4.VZV reactivationwas associatedwith exaggeratedBCG-speciﬁc IFN-γ responses.Mean (with standard error) BCG-speciﬁc IFN-γ responses detected in theﬁve high doseAERAS-422
volunteers that did not develop VZV reactivation (also excluding the one high spontaneous IFN-γ producer) are shown (A). BCG-speciﬁc IFN-γ results for the two volunteers in the high
dose AERAS-422 group that developed zoster are also shown(B).
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Fig. 5. VZV reactivations were not related to increased monocyte inﬂammatory responses alone induced by AERAS-422 or to anti-IFN-γ-speciﬁc autoimmunity. IL-1β and TNF-α inﬂam-
matory cytokine responses from ELISAs of supernatants from humanmonocyte cultures infected for 72 hwithwild type (Tice or Danish) or AERAS-422 recombinant BCG strains (MOI 30)
are shown as mean and standard error (A). Results of IFN-γ neutralization assays using plasma samples harvested on day 56 from all eight high dose AERAS-422 recipients are shown as
pg/ml for dilutions up to 10−5 (B).
283D.F. Hoft et al. / EBioMedicine 7 (2016) 278–2863.8. Associations Between Transcriptomes and Vaccine-induced Mycobac-
terial Growth Inhibition
WBA responses induced by AERAS-422 were integrated with the
PBMC transcriptomes. Longitudinal correlations between gene expres-
sion and WBA were evaluated at matching time points for matched
trial participants. Unexpectedly, across all vaccine groups and time
points, positive correlations were observed between both IL-1β and a
monocyte chemokine module and delta WBA (Supplemental Figs. 3
and 4), indicating that decreased mycobacterial killing was associated
with increased expression of myeloid associated and pro-
inﬂammatory genes.
Gene expression and WBA were integrated at the level of vaccine-
induced responses. Log2 fold-changes compared to pre-vaccination for
gene expression were directly correlated with those for WBA, at the
same or later time points. This analysis identiﬁed many genes with
strong (p b 0.005) negative Spearman rank correlations between dayFig. 6.Whole blood bactericidal activity. The anti-mycobacterial activity of whole blood
was studied usingM. bovis BCG cultured with blood samples harvested from volunteers
in the Tice and high dose AERAS-422 groups on days 0, 56, 84 and 182. The vertical axis
indicates log change mycobacterial viability per day of whole blood culture, with positive
numbers indicating growth. *p b 0.02 by Wilcoxon Matched-Pairs Test comparing pre- to
post-vaccination responses.14 expression fold-changes and day 84WBA changes (Fig. 7A). Module
enrichment analysis of these genes revealed remarkably strong associa-
tions with NK cells, T cells, and cytotoxicity (four modules with FDR
b1 × 10−10). Included among these genes was IL-12RB2, with a day
14 gene expression fold-change that robustly correlated with the day
84 WBA fold-change (r=−0.9, p= 4 × 10−4) (Supplemental Fig. 5).
These results suggest that development of robust vaccine-induced my-
cobacterial killing at late time points is associated with robust induction
of NK and cytotoxicity modules in PBMCs at earlier time points.
3.9. Gene Expression Changes Associated With VZV Reactivation
Targeted evaluations were performed to identify gene expression
patterns preferentially associated with the two volunteers that devel-
oped zoster. Despite implementing numerous analytical strategies, no
statistically signiﬁcant or otherwise compelling associations between
VZV reactivation and AERAS-422-induced gene expression responses
were identiﬁed. The only robust association between gene expression
and VZV reactivation observed was that both volunteers exhibited re-
markably higher expression of the macrophage marker F4/80-
encoding gene EMR1, irrespective of the time point analyzed and com-
pared to all other volunteers in the trial (p b 5 × 10−5; FDR ~ 12% by ex-
haustive permutation test that only evaluated the subset of genes that
were as abundantly expressed and variable as EMR1; FDR=100%with-
out pre-ﬁltering for abundance and variability; Fig. 7B).
4. Discussion
In this ﬁrst-in-human phase I trial, two of eight volunteers adminis-
tered the higher dose of AERAS-422 developed VZV reactivations 2–
3 months post-vaccination. VZV reactivation has not previously been
described as a complication of BCG vaccination. Based on the known ep-
idemiology of VZV and reactivation, the chance that both cases were
random events was estimated to be less than one in 200,000, strongly
indicating some unique feature of the vaccine and/or of the immune
response(s) induced by AERAS-422 was responsible. Hypotheses that
could explain AERAS-422 induced VZV reactivation include reaction to
intrinsic properties of PFOG137Q, effects from over-expression ofMtb an-
tigens, or an imbalance of type I vs. type II interferon responses.
In the present study, increases in perfringolysin-speciﬁc antibodies
were not identiﬁed post-vaccination in the serum of volunteers given
AERAS-422 (data not shown), suggesting that the expressed levels of
Fig. 7. Correlations between post-vaccination transcriptomal signatures, BCG immunogenicity and VZV reactivation. Exploratory hypothesis-generating analyses were performed that
integrated the transcriptome data with WBA and VZV reactivation datasets (A). Expression of EMR1 is shown for individual volunteers (B).
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Therefore, we believe it is unlikely that the PFOG137Q molecule
expressed by AERAS-422 is responsible for the VZV reactivations. No as-
sociations between the expression of several molecules involved in
immune-mediated cytotoxic activity and the VZV reactivations were
found.
It is unlikely that overexpression of Ag85A and/or Ag85B was re-
sponsible for the VZV reactivations, as extensive pre-clinical and clinical
use of these antigens in other experimental TB vaccines has been com-
pleted without reports of zoster. Overexpression of the Rv3407 antigen
has not been previously studied in any other experimental TB vaccine
clinical trial. However, we were unable to detect evidence of Rv3407-
speciﬁc immunity induced by AERAS-422 (data not shown), suggesting
only low levels of the antigen were produced in vivo.
Although type I IFN (IFN-α/IFN-β) induces important anti-viral ef-
fects and type II IFN exerts immunogenic activity against intracellular
pathogens, both type I and type II IFNs appear to have counter-
regulatory activities. Type I IFN can exacerbate Mtb infections in mice
associated with reduced CD4+ Th1 cell responses (Manca et al.,
2001) and further impair the ability of human macrophages to control
the growth of intracellular mycobacteria (Bouchonnet et al., 2002;
Teles et al., 2013). The molecular signature of active TB disease has
been characterized as potent type I IFN signaling in human neutrophils(Berry et al., 2010) and demonstrated to reduce type II IFNR expression
at the molecular level (Rayamajhi et al., 2010).
Pre-vaccination IFN-γ responses stimulated by BCG in vitro culture
with PBMC, as demonstrated in all three vaccine groups in our study
(Fig. 3B), have been seenpreviously and interpreted as either innate im-
mune responses induced by BCG inNK cells or other nonspeciﬁc cells, or
backgroundmemory T cell immunity directed against cross-reactive an-
tigens expressed by environmental organisms other than Mtb (Hoft
et al., 2002; Kemp et al., 1996; Hoft et al., 1998; Hoft et al., 1999a;
Hoft et al., 1999b; Hoft et al., 2008). Although increases in BCG-
induced responses in all three groups post-vaccination were not statis-
tically signiﬁcant (likely due to the high variability of responses and
small sample size), these innate or cross-reactive background responses
may be as important for predisposing subjects to an immunopathologic
event such as VZV reactivation as any vaccine-induced immune
responses.
A new anti-IFN-γ-speciﬁc autoimmune phenomenon has been iden-
tiﬁed that is associated with expression of certain HLA-DR/DQ alleles
during dissemination of bothmycobacterial infection and VZV reactiva-
tion (Kampitak et al., 2011; Browne et al., 2012; Chi et al., 2013), sug-
gesting a role for type II IFN responses in suppression of Mtb
replication and VZV reactivation. Combined with the high level BCG-
induced IFN-γ responses detected in the two volunteerswho developed
285D.F. Hoft et al. / EBioMedicine 7 (2016) 278–286zoster, these data engendered the possibility that these volunteers may
possess anti-IFN-γ antibodies that neutralized cytokine function. Such
an autoimmune response could lead to exaggerated IFN-γ responses
trying to compensate for neutralizing antibody activity. The two
zoster-presenting volunteers expressed HLA class II alleles previously
associated with anti-IFN-γ autoimmunity, but so did other volunteers
that did not develop zoster. Also, IFN-γ neutralizing activity was not de-
tected in plasma harvested either pre- or post-vaccination from the vol-
unteers who developed zoster, indicating that anti-IFN-γ autoimmunity
was unlikely to be responsible for a defect in IFN-γ effector function. De-
spite the lack of detected autoimmunity, the similarity of the Class II
HLA alleles between the two zoster-presenting volunteers, combined
with complete absence of similar Class I alleles, suggests an association
of VZV reactivation with Class II. Themechanisms of this potential asso-
ciation are not understood.
Whether too much type II IFN may inhibit type I IFN responses in-
volved in maintenance of VZV latency is unknown. However, both vol-
unteers who developed zoster displayed hypersensitive IFN-γ
responses after whole blood stimulation with BCG in vitro pre- and
post-vaccination, responses that were ﬁve-ten fold higher than those
observed in other high dose AERAS-422 recipients pre-vaccination and
that increased post-vaccination. Future research should investigate neg-
ative effects of type II IFN on type I IFN signaling and functional effects.
No vaccine-induced immune responses were associated with the
zoster events either in targeted immune or whole genome expression
studies. This could be due to the absence of appropriate temporal sam-
pling for the transcriptome analyses (no measurements were taken be-
fore 14 days post-vaccination), or because the processes that led to VZV
reactivation are not related to systemic inﬂammatory responses that
would be measurable in peripheral blood transcriptomes. Both volun-
teers who developed zoster were found to constitutively express higher
levels of EMR1 in their PBMCs. F4/80, the mature protein product of
EMR1, has been identiﬁed on murine microglial cells (Zhou et al.,
2013), and EMR1 has been shown to be expressed by human eosino-
phils (Legrand et al., 2014; Hamann et al., 2007), both of which could
be relevant for control of VZV in latently infected individuals. The signif-
icance of high expression of EMR1 in the two zoster volunteers is un-
clear, but could represent high myeloid activation even at baseline,
perhaps in some way inﬂuencing cross-talk between T cells and mye-
loid cells. Up-regulation of IFN-γ responses by AERAS-422 potentially
could have led to higher suppression of type I IFN control of VZV reacti-
vation. An in vitro guinea pig model for studies of VZV latency and reac-
tivation has been developed to evaluate whether high doses of IFN-γ
plus/minus activatedmyeloid cells (especially eosinophils) can increase
VZV reactivation (Chen et al., 2011; Gan et al., 2014).
In spite of the absence of robust associations between the
transcriptomes and VZV reactivation, compelling and functionally rele-
vant vaccine-induced transcriptome changes were observed that in-
volved differential regulation of genes associated with T cell, myeloid
cell, and inﬂammatory modules. Interestingly, up-regulation of the my-
eloid module-associated genes temporally matched the known peak of
in vivo BCG replication.
In this trial, an earlier andmore robust activation of NK/cytotoxic re-
sponseswas correlatedwith increased capacity ofwhole blood cell pop-
ulations to inhibit mycobacterial growth post-vaccination (Fig. 7A).
Control of mycobacterial growth is an important goal of the protective
immune response against disseminated TB disease, and therefore
these results suggest that early activation of NK/cytotoxic activity may
serve as an important new target for TB vaccine improvement. In con-
trast, monocyte inﬂammatory responses were found to be negatively
associated with mycobacterial growth inhibitory activity. This could be
due to increased myeloid cell numbers providing a larger reservoir of
target cells for infection, and/or direct interference of these cells with
mycobacterial growth inhibitorymechanisms. Combined, these correla-
tion analyses suggest that post-vaccination increases in mycobacterial
growth inhibitory activity may be a manifestation of adaptive immuneresponses that can be prevented by too much myeloid inﬂammation.
Additional work to conﬁrm the importance of these early responses
for optimal induction of protective long-term memory and effector
functions against TB is warranted, as activators of the correct early in-
nate immune responses could possess ideal adjuvant properties for sub-
unit or other vaccines.
Overall, these results suggest that the combination of an exaggerated
IFN-γ response and a myeloid activation state, resulting from vaccina-
tion with this rBCG vaccine, may have triggered an unexpected VZV re-
activation in two young and otherwise healthymale participants in this
Phase 1 study, necessitating the discontinuation of the development of
this vaccine.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.04.010.
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